Sp. Klemens et Mh. Cynamon, ACTIVITY OF KRM-1648 IN COMBINATION WITH ISONIAZID AGAINST MYCOBACTERIUM-TUBERCULOSIS IN A MURINE MODEL, Antimicrobial agents and chemotherapy, 40(2), 1996, pp. 298-301
The activity of KRM-1648, alone and in combination with isoniazid, was
compared with those of isoniazid, rifampin, and the combination of ri
fampin plus isoniazid in a murine model of tuberculosis, Four-week-old
female CD-1 mice were infected intravenously with approximately 10(7)
viable Mycobacterium tuberculosis ATCC 35801 organisms, Treatment was
started 1 week postinfection and was given by gavage 5 days per week,
The duration of the treatment phase was 12 weeks, with groups of mice
sacrificed at 2, 4, 6, 8, and 12 weeks, For the observation phase, ad
ditional groups of treated mice were sacrificed at 4, 8, 16, and 24 we
eks after the cessation of treatment, Viable cell counts were determin
ed from homogenates of the spleens and the right lungs, KRM-1648 was t
he most active single agent evaluated and resulted in no detectable CF
Us in the spleens and lungs by the end of 6 weeks of treatment. Neithe
r rifampin nor isoniazid reduced cell counts to undetectable levels, e
ven after 12 weeks of treatment, The combination of KRM-1648 plus ison
iazid was much more active than rifampin plus isoniazid, KRM-1648 plus
isoniazid resulted in the apparent sterilization of organs at 6 month
s following the cessation of treatment, The promising activity of KRM-
1648 may allow for ultra-short-course therapy of tuberculosis, i.e., t
reatment regimens of 1 months or less.